Prior Authorization

AETNA BETTER HEALTH OF ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Duavee (IL88)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois Medicaid at 1-844-242-0908.

Please contact Aetna Better Health Illinois Medicaid at 1-866-212-2851 with questions regarding the Prior Authorization process.

When conditions are met, we will authorize the coverage of Duavee (IL88).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (specify drug) Duavee (conjugated estrogens-baz	zedovijene)				
Quantity	Frequency	Stre			
Route of Administration					
Patient Information					
Patient Name:					
Patient ID:					
Patient Group No.:					
Patient DOB:					
Patient Phone:					
Prescribing Physician					
Physician Name:					
Specialty:	NPI Number:				
Physician Fax:	Physician Phone:				
Physician Address:	City, State, Zip:				
Diagnosis:	ICD Code:				
Please circle the appropriate answer	er for each question.				
1. Is the patient an adult femal	le with an intact uterus?	Υ	N		
[If no, then no further question	ons]				
Is the requested drug being of vasomotor symptoms ass	•	Υ	N		
[If no, skip to question 4]					

F	Prescriber (Or Authorized) Signature		Date			
I affirm that the information given on this form is true and accurate as of this date.						
_	Comments:					
	Experienced an inadequate treatment response or intolerance to alendronate \ Has one of the following contraindications to alendronate: [Esophageal abnormalities \ Inability to stand or sit upright for 30 minutes \ Has additional risk factors for developing osteonecrosis of the jaw \ CrCl less than 35 mL/min]					
7.	Does the patient meet one of the following:	Υ	N			
	[If no, then no further questions]					
	Experienced an inadequate treatment response or intolerance to raloxifene \ Has a history of venous thromboembolism (VTE) which is a contraindication to raloxifene					
6.	Does the patient meet one of the following:	Υ	N			
	[If no, then no further questions]					
5.	Is the patient at significant risk of osteoporosis?	Υ	N			
	[If no, then no further questions]					
4.	Is the requested drug being prescribed for the prevention of postmenopausal osteoporosis?	Y	N			
	[No further questions]					
	tablets/patch, Prempro, Estrace)? List formulary agents trialed:					
3.	Has the patient experienced an inadequate treatment response or intolerance to at least 2 formulary estrogen/progesterone products (e.g., estradiol	Y	N			